Entecavir Market

Entecavir is used to treat long-term hepatitis B infection. Hepatitis B is an infection of the liver caused by the hepatitis B virus. Long-term infection can cause liver damage, rarely liver cancer, and liver failure. Entecavir helps to decrease the amount of hepatitis B virus in your body. It is unknown if this medication lowers your chance of getting liver cancer or liver damage. Entecavir is an antiviral that belongs to a class of drugs known as hepatitis B virus nucleoside reverse transcriptase inhibitors.
Entecavir Market contains market size and forecasts of Entecavir in global, including the following market information:
Global Entecavir Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Entecavir Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Entecavir companies in 2021 (%)
The global Entecavir market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
0.5mg/Pcs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Entecavir include Zhejiang Huahai Pharmaceutical, Teva, Aurobindo, Bristol-Myers Squibb, CTTQ Pharma, DAWNRAYS, Qingfeng Pharmaceutical Group, BrightGene Bio-Medical Technology and Haisco Pharmaceutical Group, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Entecavir manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Entecavir Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Entecavir Market Segment Percentages, by Type, 2021 (%)
0.5mg/Pcs
1mg/Pcs
Global Entecavir Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Entecavir Market Segment Percentages, by Application, 2021 (%)
Adults
Children
Global Entecavir Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Entecavir Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Entecavir revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Entecavir revenues share in global market, 2021 (%)
Key companies Entecavir sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Entecavir sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Zhejiang Huahai Pharmaceutical
Teva
Aurobindo
Bristol-Myers Squibb
CTTQ Pharma
DAWNRAYS
Qingfeng Pharmaceutical Group
BrightGene Bio-Medical Technology
Haisco Pharmaceutical Group
Cosunter Pharmaceutical
Anhui Biochem
QIANJIN GROUP